Bedrosian Camille L

SEC source: 0001193125-26-390510 · ownership.xml · nonDerivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 278,064

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.85 to $33.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001193125-26-390510 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 280,145

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.76 to $32.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · derivative · entry 9

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,730 shares

Expires 2036-06-18

F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · derivative · entry 8

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,350 shares

Expires 2035-06-11

F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · derivative · entry 7

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires 2034-06-07

F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · derivative · entry 6

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires 2033-06-15

F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · derivative · entry 5

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires 2032-06-17

F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · derivative · entry 4

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires 2031-06-22

F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · derivative · entry 3

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2030-09-01

F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · nonDerivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.

SEC source: 0001628280-26-059900 · wk-form4_1788296414.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,925

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").

SEC source: 0001193125-26-359676 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,092

F1 · shares: The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

SEC source: 0001628280-26-044712 · wk-form4_1782162151.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,730

Underlying: Common Stock · 9,730 shares

Expires 2036-06-18

F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001628280-26-044712 · wk-form4_1782162151.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,225

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001193125-26-098436 · ownership.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,985

Underlying: Common Stock · 143,985 shares

Expires 2036-03-05

F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

SEC source: 0001193125-26-098436 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,285

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0001193125-26-091440 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,295

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.440 to $14.945. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001193125-25-306818 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,756

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.30 to $14.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001193125-25-228339 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,336

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $15.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001104659-25-063080 · tm2519230-3_4seq1.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,712

Underlying: Common Stock · 4,712 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-25-063080 · tm2519230-3_4seq1.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,037

Underlying: Common Stock · 7,037 shares

Expires 2035-06-23

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001104659-25-061711 · tm2518591-4_4seq1.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date.

F2 · derivative.expiration_date: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date.

SEC source: 0001104659-25-061711 · tm2518591-4_4seq1.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

SEC source: 0000950170-25-086265 · ownership.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,350

Underlying: Common Stock · 10,350 shares

Expires 2035-06-11

F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0000950170-25-086265 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,300

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0000950170-25-049567 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,375

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000950170-25-036712 · ownership.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,630

Underlying: Common Stock · 102,630 shares

Expires 2035-03-05

F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

SEC source: 0000950170-25-036712 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,800

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0000950170-24-132885 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,380

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.475 to $5.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000950170-24-111809 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,801

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.125 to $3.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001104659-24-074767 · tm2418139-3_4seq1.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date.

F2 · derivative.expiration_date: The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date.

SEC source: 0001104659-24-074767 · tm2418139-3_4seq1.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

SEC source: 0001104659-24-073634 · tm2417588-3_4seq1.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-24-073634 · tm2417588-3_4seq1.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2034-06-17

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-24-071923 · ownership.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2034-06-07

F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0000950170-24-071923 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,400

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0000950170-24-045693 · ownership.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2034-04-15

F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

SEC source: 0000950170-24-045693 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,243

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0000950170-23-066796 · ownership.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,500

Underlying: Common Stock · 162,500 shares

Expires 2033-11-26

F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on December 1, 2024, with the remainder vesting in a series of 36 successive monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.

SEC source: 0000950170-23-066796 · ownership.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,333

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 annual installments, with the first installment vesting on December 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.

SEC source: 0001104659-23-074292 · tm2319485-2_4seq1.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-23-074292 · tm2319485-2_4seq1.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-20

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001209191-23-038818 · doc4.xml · derivative · entry 2

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2033-06-15

F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-23-038818 · doc4.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001209191-23-016053 · doc4.xml · nonDerivative · entry 2

Bedrosian Camille L · CIK 0001326969 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,720

F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

SEC source: 0001209191-23-016053 · doc4.xml · nonDerivative · entry 1

Bedrosian Camille L · CIK 0001326969 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,601

F1 · shares: Represents shares of common stock into which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric.

SEC source: 0001209191-22-038435 · doc4.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

SEC source: 0001104659-22-070117 · tm2218129-2_4seq1.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 8, 2023 or (ii) the date of the Issuer's next annual meeting of the stockholders.

SEC source: 0001209191-22-015802 · doc4.xml · derivative · entry 3

Bedrosian Camille L · CIK 0001326969 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 24,900 shares

Expires 2032-03-01

F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

SEC source: 0001209191-22-015802 · doc4.xml · nonDerivative · entry 2

Bedrosian Camille L · CIK 0001326969 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,938

F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.